MedTrace Logo

Sildenafil and Uteroplacental Perfusion

NCT01107782 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2011-02-23

No results posted yet for this study

Summary

The purpose of this study is to determine whether sildenafil is effective and safe in the treatment of fetal growth restriction.

Conditions

  • Fetal Growth Retardation

Interventions

DRUG

sildenafil

50 mg TDS orally until birth

DRUG

placebo

50mg tid

Sponsors & Collaborators

  • Tehran University of Medical Sciences

    lead OTHER

Principal Investigators

  • marzieh vahid dastjerdi, M.D. · Iranian's ministery of health

  • Sayedeh Afagh Hosseini, MD. · resident of OB&GYN

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-06-30
Completion
2012-01-31

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01107782 on ClinicalTrials.gov